
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Â year: Results from the CLEAR study
Keywords: کارآزمایی بالینی; psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As